Autoimmune Encephalitis: An Unusual Presentation as Nonconvulsive Status Epilepticus

Abstract

When refractory status epilepticus (RSE) occurs in an individual without any history of epilepsy and no immediate underlying etiology is found, it is referred to as new-onset refractory status epilepticus (NORSE). This clinical scenario may be notoriously difficult to treat and does not respond to initial medications. In cases of NORSE in which an etiology is found, antibody-mediated disorders are the most common cause. Autoimmune encephalitis refers to a diverse group of neuropsychiatric disorders and can present with an array of symptoms many of which make diagnosis difficult due to similarities in clinical, imaging, and laboratory findings with respect to other forms of autoimmune or infectious encephalitis. This case report highlights how a patient with acute-onset history, showing generalized periodic epileptiform discharges on electroencephalogram (EEG) but with no prior history of seizures, was eventually diagnosed as autoimmune encephalitis based on clinical findings, cerebrospinal fluid (CSF) reports, and EEG analysis.

Keywords

autoimmune encephalitis - cerebrospinal fluid - electroencephalogram - nonconvulsive status epilepticus

Publication History

Article published online:
29 April 2019

• References

• 1 Kim H, Ryu H, Kang JK. Anti-NMDA receptor antibody encephalitis presenting with unilateral non-convulsive status epilepticus in a male patient. J Epilepsy Res 2015; 5 (01) 17-19
• 2 Goldberg EM, Taub KS, Kessler SK, Abend NS. Anti-NMDA receptor encephalitis presenting with focal non-convulsive status epilepticus in a child. Neuropediatrics 2011; 42 (05) 188-190
• 3 Young GB, Jordan KG, Doig GS. An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring: an investigation of variables associated with mortality. Neurology 1996; 47 (01) 83-89
• 4 Chong DJ, Hirsch LJ. Which EEG patterns warrant treatment in the critically ill?. Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol 2005; 22 (02) 79-91
• 5 Wilder-Smith EP, Lim EC, Teoh HL. et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singapore 2005; 34 (07) 417-420
• 6 Costello DJ, Kilbride RD, Cole AJ. Cryptogenic new onset refractory status epilepticus (NORSE) in adults-Infectious or not?. J Neurol Sci 2009; 277 (1-2) 26-31
• 7 Gaspard N, Foreman BP, Alvarez V. et al; Critical Care EEG Monitoring Research Consortium (CCEMRC). New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology 2015; 85 (18) 1604-1613
• 8 Van Ness PC. Pentobarbital and EEG burst suppression in treatment of status epilepticus refractory to benzodiazepines and phenytoin. Epilepsia 1990; 31 (01) 61-67
• 9 Toledano M, Britton JW, McKeon A. et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014; 82 (18) 1578-1586
• 10 Khawaja AM, DeWolfe JL, Miller DW, Szaflarski JP. New-onset refractory status epilepticus (NORSE)—the potential role for immunotherapy. Epilepsy Behav 2015; 47: 17-23